James Richardson
Internal Medicine · Ontario, OHNPI 1770524001
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 126 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 15.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $776 and has fallen 70.4% since, to $230 in 2022.
Across 126 payments — averaging $14.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$274
- Takeda Pharmaceuticals U.S.A., Inc.$167
- Amgen$153
- Johnson & Johnson$126
- Biohaven Pharmaceuticals, Inc.$121
- Biohaven Pharmaceutical Holding Company Ltd.$117
- plus $851 from 22 others
What the payments were for
- Food & beverage$1,77698%
- Education$312%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 15 | $274 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $167 |
| Amgen | 4 | $153 |
| Johnson & Johnson(2 entities) | 8 | $126 |
| Biohaven Pharmaceuticals, Inc. | 20 | $121 |
| Biohaven Pharmaceutical Holding Company Ltd. | 13 | $117 |
| AstraZeneca | 8 | $110 |
| Pfizer | 7 | $88 |
| Novo Nordisk | 6 | $87 |
| Kowa Pharmaceuticals America, Inc. | 5 | $72 |
| GSK | 3 | $51 |
| Astellas Pharma US Inc | 3 | $49 |
| Novartis | 3 | $45 |
| Lilly USA, LLC | 3 | $44 |
| Mylan Specialty L.p. | 3 | $41 |
| Bausch Health US, LLC | 2 | $37 |
| Sanofi-aventis U.S. LLC | 2 | $28 |
| Merck | 2 | $25 |
| AbbVie | 2 | $25 |
| Irhythm Technologies, Inc. | 1 | $24 |
| Hologic Sales And Service, LLC | 1 | $18 |
| Indivior Inc. | 1 | $18 |
| Orexo US, Inc. | 1 | $18 |
| Ironwood Pharmaceuticals, Inc | 1 | $17 |
| Circassia Inc. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Abbott | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
How this compares
$1,808 in reported general payments places this provider in the 80th percentile of 4,428 internal medicine providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 74 | $9,661 |
| Buprenorphine Hcl | 24 | $739 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Ontario
- Hassan MalikAkron$1.7M
- Cyrus HarrisCleveland$726K
- Nina DeepWesterville$614K
- Necklall KhooblallAustintown$448K
- Daniel WeissMentor$406K
- Richard KimDayton$326K
- Marina MagreyCleveland$312K
- Lisa LarkinCincinnati$276K
- Gregg FaimanMayfield Hts$274K
- Vincent MartinCincinnati$261K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.